Skip to main content

Table 1 Main features of eligible studies for pooled analysis

From: Genetic impact of methylenetetrahydrofolate reductase (MTHFR) polymorphism on the susceptibility to colorectal polyps: a meta-analysis

First author Year NOS Polymorphism Case Disease type Control Country Ethnicity Genotyping assay P HWE
A/A A/B B/B A/A A/B B/B
Al-Ghnaniem [14] 2007 7 rs1801133 22 12 1 adenomatous polyps 41 29 6 UK Caucasian PCR-RFLP 0.784
   rs1801133 11 3 3 hyperplastic polyps 41 29 6 UK Caucasian PCR-RFLP 0.784
   rs1801131 18 12 5 adenomatous polyps 47 26 3 UK Caucasian PCR-RFLP 0.799
   rs1801131 8 7 2 hyperplastic polyps 47 26 3 UK Caucasian PCR-RFLP 0.799
Ashktorab [15] 2007 6 rs1801133 18 4 0 colorectal polyps 30 5 0 USA Caucasian PCR-RFLP 0.649
Beckett [16] 2015 5 rs1801133 29 20 7 adenomatous polyps 88 91 18 Australia Caucasian PCR-RFLP 0.421
   rs1801131 28 22 6 adenomatous polyps 101 83 13 Australia Caucasian PCR-RFLP 0.460
Chen [17] 1998 8 rs1801133 102 126 30 adenomatous polyps 323 324 66 USA Caucasian PCR-RFLP 0.234
Chiang [18] 2015 7 rs1801133 44 26 0 adenomatous polyps 91 73 18 China Asian PCR-RFLP 0.553
de Vogel [19] 2011 6 rs1801133 947 714 135 adenomatous polyps 4463 3563 708 Norway Caucasian Real-time PCR 0.933
Delgado [20] 2001 8 rs1801133 6 19 7 adenomatous polyps 34 52 24 Mexico Caucasian PCR-RFLP 0.625
Giovannucci [21] 2003 6 rs1801133 157 168 49 adenomatous polyps 299 325 101 USA Caucasian PCR-RFLP 0.401
   rs1801131 186 165 24 adenomatous polyps 369 299 57 USA Caucasian PCR-RFLP 0.740
Goode [22] 2004 7 rs1801133 236 196 58 adenomatous polyps 259 238 67 USA Caucasian PCR-RFLP 0.281
Hazra [23] 2007 7 rs1801133 217 245 63 adenomatous polyps 229 232 64 USA Caucasian NA 0.658
   rs1801131 278 211 48 adenomatous polyps 264 219 46 USA Caucasian NA 0.951
Hirose [24] 2005 8 rs1801133 182 203 67 adenomatous polyps 399 496 155 Japan Asian PCR-RFLP 0.966
Yi [8] 2006 6 rs1801133 5 5 4 adenomatous polyps 2 4 0 Korea Asian PCR-RFLP 0.221
   rs1801131 10 3 1 adenomatous polyps 3 3 0 Korea Asian PCR-RFLP 0.414
Levine [25] 2000 7 rs1801133 256 163 52 adenomatous polyps 263 198 49 USA Caucasian PCR-RFLP 0.193
Lightfoot [26] 2008 8 rs1801133 135 132 41 adenomatous polyps 130 139 27 UK Caucasian Taqman drug metabolizing genotyping assays 0.238
   rs1801131 155 124 29 adenomatous polyps 140 130 26 UK Caucasian Taqman drug metabolizing genotyping assays 0.590
Marugame [10] 2000 8 rs1801133 83 92 30 adenomatous polyps 89 105 26 Japan Asian PCR-RFLP 0.555
Mitrou [27] 2006 7 rs1801133 405 376 87 adenomatous polyps 402 407 89 UK Caucasian PCR-RFLP 0.340
    rs1801131 383 375 104 adenomatous polyps 415 380 88 UK Caucasian PCR-RFLP 0.941
Pufulete [28] 2003 7 rs1801133 20 13 2 adenomatous polyps 41 29 6 UK Caucasian PCR-RFLP 0.784
   rs1801131 18 12 5 adenomatous polyps 47 26 3 UK Caucasian PCR-RFLP 0.799
Ulrich [29] 1999 9 rs1801133 258 219 50 adenomatous polyps 303 269 73 USA Caucasian PCR-RFLP 0.260
Ulrich [30] 2000 7 rs1801133 98 72 26 hyperplastic polyps 297 258 71 USA Caucasian PCR-RFLP 0.192
van den [9] 2005 7 rs1801133 343 346 79 adenomatous polyps 325 305 79 Netherlands Caucasian PCR-RFLP 0.560
Williams [31] 2013 7 rs1801133 34 48 8 adenomatous polyps 44 42 9 UK Caucasian PCR-RFLP 0.822
Yamaji [32] 2009 6 rs1801133 263 325 124 adenomatous polyps 219 324 120 Japan Asian TaqMan PCR 0.993
   rs1801131 452 228 32 adenomatous polyps 441 197 25 Japan Asian TaqMan PCR 0.609
  1. A/A C/C genotype of rs1801133, or A/A genotype of rs1801131, A/B C/T genotype of rs1801133, or A/C genotype of rs1801131, B/B T/T genotype of rs1801133, or C/C genotype of rs1801131, NA not available, PCR-RFLP polymerase chain reaction-restriction fragment length polymorphism, HWE Hardy-Weinberg Equilibrium, NOS Newcastle-Ottawa Scale